J&J strengthens skin reaction warnings for Intelence
This article was originally published in Scrip
Executive Summary
Johnson & Johnson's Tibotec Therapeutics division has strengthened US warnings about severe skin reactions with its HIV treatment Intelence (etravirine). The new language reflects postmarketing reports of a fatality due to toxic epidermal necrolysis and hypersensitivity reactions that may be accompanied by hepatic failure.